FDA for the Second Time Rejects Blood Thinner, Xarelto, for Heart Disease

by Raja Nandhini on March 7, 2013 at 6:12 AM
 FDA for the Second Time Rejects Blood Thinner, Xarelto, for Heart Disease

Johnson & Johnson (JNJ) and its partner Bayer AG (BAYN) suffered a blow when FDA rejected for the second time the extended use of Xarelto, a blood thinner, to treat heart disease and reduce the risk of heart attacks.

Xarelto is an approved drug to prevent blood clots in patients undergoing hip and knee surgeries and to prevent stroke in patients with irregular heartbeats.


Earlier in July 2012, FDA had denied the approval to use Xarelto on heart patients stating missing data of around 1000 patients towards the end of the study.

On tracking down the data from patients who withdrew from the study, the overall results were positive. The drug when used with other regular drugs had the efficiency to reduce the risk of death due to heart disease by 16%.

However, the risk of bleeding increased by nearly four times, which outweighed the efficacy of Xarelto in preventing heart attacks. This has greatly influenced FDA's decision to reject the blood thinner to treat heart patients.

Source: Medindia
Font : A-A+



Recommended Readings

Latest Drug News

Anti-Obesity Drugs' Impact on Osteoarthritis Survival
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

FDA for the Second Time Rejects Blood Thinner, Xarelto, for Heart Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests